Compare MEC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | ARVN |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.1M | 600.2M |
| IPO Year | 2019 | 2018 |
| Metric | MEC | ARVN |
|---|---|---|
| Price | $19.11 | $8.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $24.33 | $15.05 |
| AVG Volume (30 Days) | 448.1K | ★ 547.9K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | ★ N/A | $5.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.25 | $6.97 |
| 52 Week High | $38.76 | $14.22 |
| Indicator | MEC | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 26.26 | 44.25 |
| Support Level | $17.20 | $8.37 |
| Resistance Level | $19.42 | $8.90 |
| Average True Range (ATR) | 0.99 | 0.32 |
| MACD | 0.17 | -0.10 |
| Stochastic Oscillator | 2.39 | 18.90 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.